The MGDRx EyeBag, a device designed to treat meibomian gland dysfunction, effectively relieves dry eye symptoms, according to a recent study. However, there seems to be little effect on MG function and tear stability.
New drug applications approved by US FDA as of 1 - 15 October 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Treatment with ranibizumab has resulted in robust visual acuity and anatomic improvement in eyes with concurrent diabetic macular oedema (DME) and baseline macular nonperfusion (MNP) despite having worse vision or increased central subfield thickness (CST), according to a posthoc analysis of RIDE and RISE, two phase III randomized controlled trials.
Early intravitreal implantation of the corticosteroid dexamethasone at an interval of ≥4 months provided rapid and significant improvement in best-corrected visual acuity (BCVA) and central retinal thickness (CRT) in patients with macular oedema following branch retinal vein occlusion (BRVO), according to the COBALT* study.
The prostaglandin analogue latanoprost demonstrates an acceptable safety profile in the long-term treatment of paediatric patients with glaucoma and ocular hypertension, with no evidence of clinically meaningful changes in ocular development or hyperpigmentation, according to the results of a 3-year safety study of the drug.
applications approved by US FDA as of 1 - 15 September 2018 which includes New Molecular Entities (NMEs) and new
biologics. It does not include Tentative Approvals. Supplemental approvals
may have occurred since the original approval date.
Administering conbercept at a dose of 0.5 mg once monthly for the first 3 months then once quarterly until month 12 appears to be effective in the treatment of age-related macular degeneration, with significant improvements in visual acuity observed at month 3 and maintained through 1 year, according to the results of the phase III PHOENIX trial.
Men who undergo flexible cystoscopy, particularly with a longer dwell time, may benefit from intraurethral lidocaine as it provides significant pain reduction, suggest the results of a meta-analysis. Evidence is lacking for other tested interventions.
While douching is not associated with the risk of ovarian cancer, the combination of talc and commercially available douches contributes to a modest increase in the risk of epithelial ovarian cancer beyond that conferred by talc use alone, as shown in a recent study.